Jobs
-
Nearly 500 people attended the first day of the 2011 Drug Delivery to the Lungs meeting (DDL 22) at the Edinburgh International Conference Centre. Approximately 50 of the DDL 22 attendees were also registered for… Read more . . .
-
Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI… Read more . . .
-
Swedish pharma company Meda released a statement regarding a new patent for its Astepro nasal spray that reads in its entirety: “The United States Patent and Trademark Office (USPTO) today issued a patent related to… Read more . . .
-
Consort Medical, parent company of device developer and manufacturer Bespak, reports “strong volume growth” for Bespak’s inhaler business for the six months ending October 31, 2011. Bespak revenues were up 17% from 2010, with operating… Read more . . .
-
Acacia Research, a California company frequently described as a “patent troll,” says that it has acquired 13 patents for inhaler technology from “a major medical company.” Company CEO Paul Ryan said, “Acacia continues to increase… Read more . . .
-
Bloomberg has published an article about GSK’s overhaul of its R&D organization that describes former head of the allergic inflammation discovery performance unit Roberto Solari as “one of the casualties of the company’s new approach… Read more . . .
-
AstraZeneca has asked the New Zealand High Court to review a decision by Pharmac, the government drug purchasing agency, to reduce its subsidy for the Symbicort Turbuhaler to achieve pricing parity with GSK’s Seretide (Advair)… Read more . . .
-
The Michael J. Fox Foundation (MJFF) for Parkinson’s Research (MJFF) has awarded a grant to Civitas Therapeutics to support development of the company’s lead product, CVT-301, an inhaled levodopa (L-dopa) formulation for the treatment of… Read more . . .
-
Shortly after announcing a co-promotion deal with Eisai for its inhaled COPD drugs in Japan, Novartis has filed a new drug application in that country for one of those drugs, NVA237 inhaled glycopyrronium bromide, according… Read more . . .
-
According to a study published in the November 24 issue of the New England Journal of Medicine, intermittent administration of a high dose of inhaled budesonide resulted in no more exacerbations over the course of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland